相关实验视频

Updated: Aug 10, 2026

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

通过德克萨德罗斯塔特酸盐抑制CYP11B2的结构和临床特征

Emanuele Pignatti¹, Jakub Kollar², Evelyn Hafele²

¹Department of Pediatric Endocrinology, Diabetology and Metabolism, University Hospital Inselspital, University of Bern, 3010 Bern, Switzerland; Department for BioMedical Research, University Hospital Inselspital, University of Bern, 3010 Bern, Switzerland.

The Journal of steroid biochemistry and molecular biology

|October 12, 2023

概括

德克斯法德罗斯酸盐有效抑制阿尔多素合成酶 (CYP11B2),这是心血管疾病的关键标. 临床研究表明,它可以降低阿尔多斯特水平,而不会影响其他类固醇激素.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
内分泌学在内分泌学.

背景情况:

阿尔多氨酸合成酶 (CYP11B2) 是一种关键的药物标,因为它在心血管疾病和初级阿尔多氨酸性疾病中的作用.
CYP11B2的遗传失调与心血管问题和盐浪费综合征有关.
德克斯法德洛斯塔特酸盐已成为一种强大的CYP11B2抑制剂.

研究的目的:

为了描述德克斯法德洛斯塔特酸盐的药.
阐明德克斯法德洛斯塔特与CYP11B2,CYP11B1和CYP19A1.1之间基于结构的酶协调.
为了确认体外和体内Dexfadrostat酸盐的疗效和特异性.

主要方法:

基于结构的酶协调研究与CYP11B2,CYP11B1和CYP19A1.1.
在体外类固醇周转量测试.
临床第一阶段研究涉及健康受试者.
尿中代谢物的分析 (阿尔多,皮质,脱氧皮质,,雌激素).

主要成果:

德克斯法德罗斯塔特精确地与CYP11B2的活性部位协调,形成一个稳定的复合体.
德克斯法德洛斯塔特与CYP11B1或CYP19A1.1没有显示可信的协调.
在体外和临床研究中证实了德克斯法德罗斯塔特对CYP11B2.2的选择性抑制.
临床治疗导致了剂量依赖的阿尔多激素抑制和增加的皮质激素代谢物,表明CYP11B2抑制.
没有观察到对CYP19A1的非目标影响,和雌激素水平稳定.

结论:

德克斯法德洛斯塔特具有选择性结合和抑制CYP11B2.2的理想结构特征.
德克斯法德洛斯塔特酸盐通过抑制CYP11B2.2,在体内有效抑制阿尔多素水平.
药物的特异性表明,在治疗与阿尔多激素过量相关的疾病方面,该药物具有有利的特征.

关键词:

阿尔多氨酸是一种阿尔多氨酸.在CYP11B2中.德克斯法德洛斯塔特酸盐的使用

更多相关视频

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

相关概念视频

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).